Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 4, 2007, Pages 916-922

  Blanco Colio, Luis M ^a,d   Martín Ventura, Jose L ^b   Muñóz García, Begoña ^a   Orbe, Josune ^c   Páramo, Jose A ^c   Michel, Jean Baptiste ^b   Ortiz, Alberto ^a   Meilhac, Olivier ^b   Egido, Jesús ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b INSERM   (France)

^c UNIVERSITY OF NAVARRA   (Spain)

^d Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Atherosclerosis; Carotid arteries; Plasma

Indexed keywords

BIOLOGICAL MARKER; PROTEIN DERIVATIVE; SOLUBLE TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTERY DIAMETER; ARTERY INTIMA; ARTERY MEDIA; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CAROTID ARTERY; CAROTID ARTERY OBSTRUCTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; SUPERNATANT; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; WESTERN BLOTTING;

AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CAROTID ARTERIES; CAROTID STENOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; SEVERITY OF ILLNESS INDEX; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR NECROSIS FACTORS;

EID: 34247132376     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000258972.10109.ff     Document Type: Article

References (30)

1. Aikawa M, Libby P. The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Can J Cardiol. 2004;20:631-634.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
3. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, Summaria F, Ginnetti F, Fadda G, Maseri A. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 1999;99:855-860.
4. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331:417-424.
5. Libby P, Ridker PM. Novel inflammatory markers of coronary risk: Theory versus practice. Circulation. 1999;100:1148-1150.
6. Duran MC, Mas S, Martín-Ventura JL, Meilhac O, Michel JB, Gallego-Delgado J, Lazaro A, Tunon J, Egido J, Vivanco F. Proteomic analysis of human vessels: application to atherosclerotic plaques. Proteomics. 2003;3:973-978.
7. Martin-Ventura JL, Duran MC, Blanco-Colio LM, Meilhac O, Leclercq A, Michel JB, Jensen ON, Hernandez-Merida S, Tunon J, Vivanco F, Egido J. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation. 2004;110:2216-2219.
8. Seibert V, Wiesner A, Buschmann T, Meuer J. Surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI TOF-MS) and ProteinChip technology in proteomics research. Pathol Res Pract. 2004;200:83-94.
9. Paramo JA, Orbe J, Beloqui O, Benito A, Colina I, Martinez-Vila E, Diez J. Prothrombin fragment 1+2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease. Stroke. 2004;35:1085-1089.
10. Greenland P, Smith SC, Grundy SM. Improving coronary heart disease assessment in asymptomatic people. Role of traditional risk factors and non-invasive cardiovascular tests. Circulation. 2001;104:1863-1867.
11. Beloqui O, Paramo JA, Orbe J, Benito A, Colina I, Monasterio A, Diez J. Monocyte cyclooxygenase-2 overactivity: a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors?. Eur Heart J. 2005;26:153-158.
12. Blanco-Colio LM, Martin-Ventura JL, Sol JM, Diaz C, Hernandez G, Egido J. Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin. J Am Coll Cardiol. 2004;43:1188-1194.
13. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia I, Browning JL. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem. 1997;272:32401-32410.
14. Schneider P, Schwenzer R, Haas E, Muhlenbeck F, Schubert G, Scheurich P, Tschopp J, Wajant H. TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur J Immunol. 1999;29:1785-1792.
15. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572-577.
16. Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev. 2003;14:241-249.
17. Harada N, Nakayama M, Nakano H, Fukuchi Y, Yagita H, Okumura K. Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun. 2002;299:488-493.
18. Kim SH, Kang YJ, Kim WJ, Woo DK, Lee Y, Kim DI, Park YB, Kwon BS, Park JE, Lee WH. TWEAK can induce proinflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J. 2004;68:396-399.
19. Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S. TWEAK induces NF-kappaB2 p 100 processing and long lasting NF-kB activation. J Biol Chem. 2000;278:36005-36012.
20. Munoz-Garcia B, Martin-Ventura JL, Martinez E, Sanchez S, Hernandez G, Ortega L, Ortiz A, Egido J, Blanco-Colio LM. Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin. Stroke. 2006;37:2044-2053.
21. Maecker H, Varfolomeev E, Kischkel F, Lawerence D, LeBlanc H, Lee W, Hurst S, Danilenko D, Li J, Filvaroff E, Yang B, Daniel D, Ashkenazi A. TWEAK attenuates the transition from innate to adaptive immunity. Cell. 2005;123:931-944.
22. Chicheportiche Y, Fossati-Jimack L, Moll S, Ibnou-Zekri N, Izui S. Downregulated expression of TWEAK mRNA in acute and chronic inflammatory pathologies. Biochem Biophis Res Commun. 2000;279:162-165.
23. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation. 1997;128:262-269.
24. Paramo JA, Beloqui O, Colina I, Diez J, Orbe J. Independent association of von Willebrand factor with surrogate markers of atherosclerosis in middle-aged asymptomatic subjects. J Thromb Haemost. 2005;3:662-664.
25. Paramo JA, Beloqui O, Roncal C, Benito A, Orbe J Validation of plasma fibrinogen as a marker of carotid atherosclerosis in subjects free of clinical cardiovascular disease. Haematologica. 2004;89:1226-1231.
26. Martín-Ventura JL, Blanco-Colio, Muñoz-Garcia B, Gomez-Hernandez A, Arribas A, Ortega L, Tunon J, Egido J. NF-kappaB activation and Fas ligand overexpression in blood and plaques of patients with carotid atherosclerosis: potential implication in plaque instability. Stroke. 2004;35:458-463.
27. Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Martineau P, Hérnandez G, Egido J, Increased Soluble Fas Plasma Levels in Subjects at High Cardiovascular Risk. Atorvastatin on Inflammatory Markers (AIM) Study, a Substudy of ACTFAST. Arterioscler Thromb Vasc Biol. 2007;27:168-174.
28. Michowitz Y, Goldstein E, Roth A, Afek A, Abashidze A, Gal YB, Keren G, George J. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol. 2005;45:1018-1024.
29. Winkles JA, Tran NL, Berens ME. TWEAK and Fn14: New molecular targets for cancer therapy? Cancer Let. 2006;235:11-17.
30. Campbell S, Michaelson J, Burkly L, Putterman C. The role of TWEAK/Fn14 IN the pathogenesis of inflammation and systemic autoimmunity. Front Biosci. 2004;9:2273-2284.